Estrella Immunopharma, Inc. - 10-Q Filing

Estrella Immunopharma reports Q3 2026 results with ongoing going concern disclosures and significant R&D/G&A expense activity.

SEC EDGAR ·

Tickers: $ESLA

Read the full article at SEC EDGAR

More Regulatory news